F Cappuzzo1, G Tallini2, G Finocchiaro3, R S Wilson4, C Ligorio2, L Giordano5, L Toschi3, M Incarbone3, R Cavina3, L Terracciano6, M Roncalli7, M Alloisio3, M Varella-Garcia4, W A Franklin4, A Santoro3. 1. Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano. Electronic address: federico.cappuzzo@humanitas.it. 2. Department of Pathology, Ospedale Bellaria, Bologna, Italy. 3. Department of Oncology-Hematology, Istituto Clinico Humanitas Istituto di Ricerca a Carattere Scientifico (IRCCS), Rozzano. 4. University of Colorado Cancer Center, Aurora, CO, USA. 5. Statitistic Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Italy. 6. Division of Molecular Pathology, University Hospital, Basel, Switzerland. 7. Department of Pathology, University of Milan School of Medicine, Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
Abstract
BACKGROUND: The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLC patients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections. RESULTS: A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status. CONCLUSIONS: IGF1R expression does not represent a prognostic factor in resected NSCLC patients. Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.
BACKGROUND: The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1 (IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC). Patient characteristics and methods: This retrospective study was conducted in 369 stage I-II-IIIA, surgically resected, NSCLCpatients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded. IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections. RESULTS: A positive IGF1R expression (score > or = 100) was observed in 282 cases (76.4%) and was significantly associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used (45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients in a subgroup of stage I-II adenocarcinoma (n = 137) with known EGFR mutation and copy number status. CONCLUSIONS:IGF1R expression does not represent a prognostic factor in resected NSCLCpatients. Patients with squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the different sensitivity to anti-IGF1R agents observed in clinical trials.
Authors: Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang Journal: Clin Cancer Res Date: 2011-10-31 Impact factor: 12.531
Authors: Jin-Soo Kim; Edward S Kim; Diane Liu; J Jack Lee; Luisa Solis; Carmen Behrens; Scott M Lippman; Waun Ki Hong; Ignacio I Wistuba; Ho-Young Lee Journal: Cancer Date: 2011-09-22 Impact factor: 6.860
Authors: Mark W Ball; Stephania M Bezerra; Alcides Chaux; Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Trinity J Bivalacqua; George J Netto; Arthur L Burnett Journal: Urology Date: 2016-02-18 Impact factor: 2.649
Authors: Antonio Gualberto; Marisa Dolled-Filhart; Mark Gustavson; Jason Christiansen; Yu-Fen Wang; Mary L Hixon; Jennifer Reynolds; Sandra McDonald; Agnes Ang; David L Rimm; Corey J Langer; Johnetta Blakely; Linda Garland; Luis G Paz-Ares; Daniel D Karp; Adrian V Lee Journal: Clin Cancer Res Date: 2010-07-29 Impact factor: 12.531
Authors: V Ludovini; A Flacco; F Bianconi; M Ragusa; J Vannucci; G Bellezza; R Chiari; V Minotti; L Pistola; F R Tofanetti; A Siggillino; E Baldelli; A Sidoni; N Daddi; F Puma; M Varella-Garcia; L Crinò Journal: Cancer Chemother Pharmacol Date: 2013-01-12 Impact factor: 3.333